SLC9A1 and myasthenia gravis: From the opposite point of view of cancer etiopathogenesis, namely, therapeutics, the pharmacological targeting and inhibition of NHE1 and other ion transporters, pumps and voltage gated sodium channels, is fundamental in inhibiting both local growth and the different stages of the metastatic process, either in MG and/or in a variety of other extracranial malignant tumors [70,71,72,73,74,75,76,77].